1SRPT Stock Overview

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. More details

1SRPT fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 46% below our estimate of its fair value

Earnings are forecast to grow 47.63% per year

Risk Analysis

Shares are highly illiquid

Has less than 1 year of cash runway

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Sarepta Therapeutics, Inc. Competitors

Philogen

BIT:PHIL

€878.3m

Ulisse Biomed

BIT:UBM

€18.3m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.8b

Suzhou Zelgen BiopharmaceuticalsLtd

SHSE:688266

CN¥24.3b

Price History & Performance

Summary of share price highs, lows and changes for Sarepta Therapeutics
Historical stock prices
Current Share Price	US$33.40
52 Week High	US$33.64
52 Week Low	US$33.64
Beta	0.84
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-37.31%

Recent updates

Shareholder Returns

	1SRPT	IT Biotechs	IT Market
7D	-40.8%	-7.7%	2.0%
1Y	n/a	-0.2%	12.5%

Return vs Industry: Insufficient data to determine how 1SRPT performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1SRPT performed against the Italian Market.

Price Volatility

Is 1SRPT's price volatile compared to industry and market?
1SRPT volatility
1SRPT Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.5%
Market Average Movement	5.4%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.3%

Stable Share Price: 1SRPT's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1SRPT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1980	1,372	Doug Ingram	www.sarepta.com

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program.

Sarepta Therapeutics, Inc. Fundamentals Summary

How do Sarepta Therapeutics's earnings and revenue compare to its market cap?
1SRPT fundamental statistics
Market cap	€3.17b
Earnings (TTM)	-€221.21m
Revenue (TTM)	€1.99b

1.6x

P/S Ratio

-14.4x

P/E Ratio

Is 1SRPT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1SRPT income statement (TTM)
Revenue	US$2.23b
Cost of Revenue	US$1.78b
Gross Profit	US$449.69m
Other Expenses	US$698.08m
Earnings	-US$248.39m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-2.53
Gross Margin	20.14%
Net Profit Margin	-11.12%
Debt/Equity Ratio	99.6%

How did 1SRPT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 19:08
End of Day Share Price	2025/05/09 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sarepta Therapeutics, Inc. is covered by 53 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Huidong Wang	Barclays
Zhiqiang Shu	Berenberg

Sarepta Therapeutics BIT:1SRPT Stock Report